{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:37:34Z","timestamp":1781714254137,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jhep.2018.09.030","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T23:09:47Z","timestamp":1540422587000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia"],"prefix":"10.1016","volume":"70","author":[{"given":"Jenny","family":"Iversen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Catlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.09.030_b0005","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/cid\/civ197","article-title":"Hepatitis C virus therapeutic development: in pursuit of \u201cperfectovir\u201d","volume":"60","author":"Dore","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2018.09.030_b0010","series-title":"Combating hepatitis B and C to reach elimination by 2030","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.jhep.2018.09.030_b0015","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.09.030_b0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.09.030_b0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.09.030_b0030","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org\/ (accessed June 28, 2018). 2018."},{"key":"10.1016\/j.jhep.2018.09.030_b0035","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.030_b0040","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jhep.2018.09.030_b0045","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.09.030_b0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","article-title":"Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation","volume":"65","author":"Martin","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.030_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(17)30284-4","article-title":"Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe","author":"Marshall","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.09.030_b0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2018.09.030_b0065","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.drugpo.2015.07.004","article-title":"Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis","volume":"26","author":"Smith","year":"2015","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jhep.2018.09.030_b0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1475-9276-10-15","article-title":"The hidden inequity in health care","volume":"10","author":"Starfield","year":"2011","journal-title":"Int J Equity Health"},{"key":"10.1016\/j.jhep.2018.09.030_b0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.idc.2018.02.006","article-title":"Elimination of hepatitis C virus in Australia: laying the foundation","volume":"32","author":"Dore","year":"2018","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jhep.2018.09.030_b0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2468-1253(16)30075-9","article-title":"Hepatitis C treatment as prevention: evidence, feasibility, and challenges","volume":"1","author":"Hajarizadeh","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.09.030_b0085","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2105\/AJPH.2012.301206","article-title":"Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: A linkage study","volume":"103","author":"Iversen","year":"2013","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jhep.2018.09.030_b0090","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/hep.23407","article-title":"Dried blood spot for hepatitis C virus serology and molecular testing","volume":"51","author":"Tuaillon","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.09.030_b0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/jvh.12628","article-title":"Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis","volume":"24","author":"Esmaeili","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2018.09.030_b0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.drugpo.2017.06.007","article-title":"Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996\u20132015","volume":"47","author":"Graham","year":"2017","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jhep.2018.09.030_b0105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1753-6405.2011.00743.x","article-title":"Higher HCV antibody prevalence among Indigenous clients of needle and syringe programs","volume":"35","author":"Ward","year":"2011","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.jhep.2018.09.030_b0110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jvh.12129","article-title":"Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999\u20132011","volume":"21","author":"Iversen","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2018.09.030_b0115","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jvh.12183","article-title":"Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study","volume":"21","author":"Treloar","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2018.09.030_b0120","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0140-6736(16)30466-4","article-title":"Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees","volume":"388","author":"Dolan","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.09.030_b0125","unstructured":"Razavi H. Only 12 countries on track to eliminate hepatitis C infection by 2030. Presented at the Global Hepatitis Summit; 14\u201317 June 2018; Toronto, Canada 2018."},{"key":"10.1016\/j.jhep.2018.09.030_b0130","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians' views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs","volume":"51","author":"Asher","year":"2016","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.jhep.2018.09.030_b0135","unstructured":"Razavi H. Modelling the impact of hepatitis C virus (HCV) treatment as prevention among people who inject drugs (PWIDs) in Australia. Presented at the 4th International Symposium on Hepatitis in Substance Users 2015."},{"key":"10.1016\/j.jhep.2018.09.030_b0140","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/QAI.0b013e31816a1d68","article-title":"Representativeness of injecting drug users who participate in HIV surveillance: results from Australia's Needle and Syringe Program Survey","volume":"47","author":"Topp","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2018.09.030_b0145","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/09595230801956116","article-title":"Acceptability of hepatitis C virus testing methods among injecting drug users","volume":"27","author":"White","year":"2008","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.jhep.2018.09.030_b0150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcv.2014.01.014","article-title":"Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens","volume":"59","author":"Dokubo","year":"2014","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2018.09.030_b0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.drugpo.2017.05.032","article-title":"Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting","volume":"47","author":"Read","year":"2017","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jhep.2018.09.030_b0160","doi-asserted-by":"crossref","first-page":"496","DOI":"10.5694\/j.1326-5377.2010.tb03605.x","article-title":"Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C","volume":"192","author":"Boonwaat","year":"2010","journal-title":"Med J Aust"},{"key":"10.1016\/j.jhep.2018.09.030_b0165","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/add.13197","article-title":"Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study","volume":"111","author":"Grebely","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jhep.2018.09.030_b0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.drugpo.2017.06.001","article-title":"'I didn't want to let it go too far'. The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: the LiveRLife study","volume":"47","author":"Marshall","year":"2017","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jhep.2018.09.030_b0175","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","article-title":"Micro-elimination \u2013 a path to global elimination of hepatitis C","volume":"67","author":"Lazarus","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.030_b0180","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/joim.12740","article-title":"Treatment as prevention for hepatitis C (TraP Hep C) \u2013 a nationwide elimination programme in Iceland using direct-acting antiviral agents","volume":"283","author":"Olafsson","year":"2018","journal-title":"J Intern Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818324942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818324942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:35:19Z","timestamp":1759174519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818324942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0168827818324942"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.09.030","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}